fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Safety and efficacy profile of Lupkynis (voclosporin) for people with lupus nephritis presented at European Alliance of Associations for Rheumatology Congress – Aurinia Pharma

Written by | 25 Jun 2024

Aurinia Pharmaceuticals Inc. announced an oral presentation at the European Alliance of Associations for Rheumatology (EULA R) 2024 taking place in Vienna, Austria June 12-15. The data reinforces… read more.

Long term phase III data published in Arthritis & Rheumatology shows Lupkynis preserved kidney function up to three years in lupus nephritis patients with no new or unexpected adverse events – Aurinia Pharma

Written by | 28 Jul 2023

Aurinia Pharmaceuticals Inc. announced that full results from the Phase III, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the official peer-reviewed journal… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.